Fritsché R, Borel Y
Nestlé Research Centre, Lausanne, Switzerland.
J Allergy Clin Immunol. 1994 Apr;93(4):778-86. doi: 10.1016/0091-6749(94)90258-5.
We have shown that, under certain conditions, a single dose of a conjugate of beta-lactoglobulin linked to isologous IgG suppresses specific antibody responses (IgE, IgG, and IgA) in rats immunized with beta-lactoglobulin. This suppression is allergen specific. It also appears to be effective when animals are first immunized and then tolerized. In addition, administration of the beta-lactoglobulin-IgG tolerogen abolishes mast cell mediator release. This has been shown both in vivo and with passively sensitized mast cells in vitro. We propose that the construction of a tolerogen made of whole protein allergen linked to IgG could provide a novel specific therapy for allergic reactions.
我们已经表明，在某些条件下，单剂量的与同种IgG连接的β-乳球蛋白缀合物可抑制用β-乳球蛋白免疫的大鼠的特异性抗体反应（IgE、IgG和IgA）。这种抑制是变应原特异性的。当动物先免疫然后耐受时，它似乎也有效。此外，给予β-乳球蛋白-IgG耐受原可消除肥大细胞介质的释放。这已在体内和体外被动致敏的肥大细胞中得到证实。我们提出，构建由与IgG连接的全蛋白变应原制成的耐受原可为过敏反应提供一种新型的特异性疗法。
